Therapeutic potential of psychedelics in substance use disorders
|
|
- Easter Richardson
- 5 years ago
- Views:
Transcription
1 Therapeutic potential of psychedelics in substance use disorders Randy T Brown MD, PhD, FASAM Associate Professor randy.brown@fammed.wisc.edu Conflicts of Interest Statement No conflicts of interest to report concerning this presentation 1
2 Funding Support Acknowledgements Collaborators Outline Psilocybin and MDMA Background Safety and Abuse potential Dosing and Administration Protocol Relevant studies Possible Mechanisms Considerations 2
3 Psilocybin Background Psychedelic: Mind manifesting capability, revealing or having useful or beneficial properties of the mind (Osmond, 1957) Psychedelic: Classics: mind manifesting Psilocybin, Mescaline, capability, DMT, revealing LSD or having useful Psilocybin or beneficial (psilocin) properties is a 5 HT2a, of the 1a receptor mind (Osmond, agonist 1957) Schedule I since 1970 Controlled Substance Act in US Classic psychedelics: psilocybin, mescaline, DMT, LSD No currently accepted medical use A high potential for abuse 3
4 Some Past and Current Modern Psilocybin Studies Zurich (2000 ): Neuroimaging Hopkins ( ): Mystical Experience, Dosing, Personality UCLA (2010): Cancer patients New Mexico (2015): Alcohol dependence Hopkins (2016): Tobacco cessation UCL/Kings College (2016 ): Depression (Open label) UCL (2013 ): Neuroimaging NYU/Hopkins (2016): Depression/anxiety in terminal cancer UW Madison (2016; 2019): High dose PK; Opioid; Depression UA Birmingham (2016 ): Cocaine use disorder Safety No evidence of neurotoxic effects Transient BP/HR Possible headache within 24 hours after dosing Impairs judgement thus context, support, and preparation are important No withdrawal Low risk of hallucinogen persisting perceptual disorder (HPPD) Negative interaction with serious psychiatric diagnoses (e.g. psychosis, bipolar) 4
5 Population Data Lower mental illness rates 1 Reduced odds of past month psychologic distress, past year suicidal thinking, past year suicidal planning, or past year suicide attempt 2 Decreased rate of supervision failure in inmates 3 1 Krebs et al. (2013). PLoS One; NSDUH; 2 Hendricks et al. (2015). JoPsychopharm; NSDUH; 3 Hendricks et al. (2014). J Ppsychopharm Dosing Typical: mg/kg UW Study: mg/kg ( mg) Oral onset: ~30 60 min Peak effects: ~2 hours 1 5 doses /4 6 weeks Total duration: 4 8 hours 5
6 Psilocybin Protocol Comprehensive psychiatric/psychological and medical screening Two monitors/guides/therapists/facilitators Study physician(s) & research coordinator(s) In a safe, secure, and supportive setting 6 8 hours of pre dosing counseling before initial dose Eye shades, headphones for pre set music playlist May stay overnight or discharge under care of their support person Integration session the next morning Phone check ins and additional integration sessions prior to next dose The UW SETTing Set: person s psychological state Pre dose preparation Careful screening Expectations/concerns Integration Setting: environment & context Interpersonal support Safe & secure room Room with comfortable & positive décor Personal objects if possible 6
7 Psilocybin Session Psychedelic vs psycholytic therapy Non directive approach, guiding when necessary Centering or personal ritual Lay down and relax into their experience Emotional support and reassurance Agreement that they would let us know if they need help Help participant be curious about their experience ( Trust, Let Go, Be Open ) Challenging Experience ( In and through ) Johns Hopkins Treatment room courtesy of MAPS Mystical Experience, Ego Dissolution & Challenging Experiences Mystical Experience 1 Mystical (Unity, Noetic, Sacred) Transcendence of time and space Deeply felt positive mood Ineffability Ego Dissolution 2 Dissolution of my self or ego One with the universe Sense of union with others Decrease sense of importance Disintegration of self or ego Less absorbed by my own issues and concerns Challenging Experiences 3 Fear Grief Isolation Experience of dying Insanity Physio distress Paranoia 1 Maclean et al (2012). J for the Scientific Study of Religion; 2 Nour (2016). Frontiers in Human Neuroscience; 3 Barrett (2017). Human Psychopharm Clin & Exp. 7
8 Mystical Experience Meaningfulness, Well Being, Spirituality, Positive Behavior Personality Dimension of Openness Griffiths et al. (2008). J of Psychopharmacology Maclean et al.(2011). J of Psychopharmacology Greater whole brain communication Psilocin similar in structure to serotonin 5 HT2a receptors* Pretreatment with ketanserin Greater communication between various major brain hub networks Decreased communication within hubs. Default mode network which together represents self related functioning Self referential processing, selfawareness, metacognition Decreased activity correlates with degree of ego dissolution Carhart Harris et al. (2014). Frontiers in Human Neuroscience 8
9 Psilocybin for Alcohol Use Disorder Bogenschutz et al. (2015) J Psychopharmacol, 1 11 N = 10 adults with DSM IV AUD pilot study 12 Psychosocial sessions 7 Motivational Enhancement Therapy 3 Psilocybin session preparation sessions 2 Post psilocybin integration sessions 2 doses of oral psilocybin one month apart 0.3mg/kg, and mg/kg (7 received dose 2) Figure 3. Drinking outcomes and effect sizes.means shown are for all available data (n = 10 at baseline, n = 9 at all other time points). p-values are from paired t-tests (df = 8). 9
10 Psilocybin for Tobacco Cessation Johnson et al. (2014) J Psychopharmacol, Johnson et al. (2017) J Am J Drug Alcohol Abuse, N = 15 adults Average of 6 failed attempts to stop smoking Cognitive Behavioral Therapy (CBT) Quit date concurrent with first of 3 psilocybin doses 2 3 oral doses of 20 30mg/70kg one month apart 12 of 15 (80%) were cotinine free (urine) at 6 months after quit date 10 of 15 (67%) were abstinent at 12 months Psilocybin for Tobacco Cessation Johnson et al. (2017) J Am J Drug Alcohol Abuse, Linear regression of Mystical Experience and long term change in cotinine 10
11 Possible therapeutic time course and stages of psilocybin Majic et al.(2015). J of Psychopharmacology Psilocybin/Classic Psychedelics Drug Participant Setting Acute Brain Effects Acute Psychological Effects Direct effects on 5 HT receptors Secondary effects e.g. glutamate receptors Changes in CBF, BOLD, Connectivity, MEG Mystical experience, ego dissolution, insight, experience of awe, unconstrained thought, autobiographical content, exposure to challenging representations, positive affect Integration through counseling + meditation, social support, art, music, nature, etc. Long term neuroplastic and functional changes Positive mood, decreased anxiety, fear, rumination, craving, distress Persisting Effects Changes in personality openness, prosocial motivation Changes in beliefs & values gratitude, mindfulness, spirituality, relationships, nature Adapted from Bogenshutz & Pommy. (2012). Drug Testing & Analysis 11
12 UW Opioid Use Disorder Study Without concurrent MAT, opioid overdose is a major risk There may be a buprenorphine psilocybin interaction based on mouse data 12 adults stable on buprenorphine MAT for 6 months to receive doses of psilocybin at a monthly interval Initial step toward efficacy study of psilocybin + MAT for Opioid Use Disorder (improve retention/use rates?) 23 MDMA 3,4 Methylenedioxymethamphetamine 12
13 Background 1912 Invented by Merck 1978 Used as an adjunct to psychotherapy Emergency Scheduling Act in 1985/86 MDMA binds 5 HT transporter Release/reuptake inhibition of NE and DA Increases affiliative neurohormones oxytocin and vasopressin Safety Transient BP/HR/temp Jaw tension, nausea, blurred vision, appe te Lack of evidence of neurocognitive decline associated with MDMA in PTSD trial 1 No misuse/dependence in PTSD trial patients 1 Limited evidence of structural or functional brain alterations in moderate MDMA users 2 Post MDMA may lead to short term neurochemical depletion, feelings of anhedonia, lethargy, anger, insomnia, decreased appetite, and depression in recreational users 3 1 Mithoefer et al. (2013). J of Psychopharm; 2 Mueller et al. (2013). Neurosci & BioBehav Rev.; 3 Parrot (2014). J of Psychoactive Drugs 13
14 Neurobiology MDMA Effects Decrease Anxiety/Depression Alter perception of meaning Increase levels of arousal Increase relaxation Improve fear extinction learning Increase emotional attachment, trust, empathy Reduce subjective fear response on recall Effects relate to PTSD symptoms Positive mood and less avoidance of therapy and emotions See old problems in a new light Increase motivation to engage; cognitive process; recount trauma Reduces hypervigilance Reflect on traumatic memory without being overwhelmed Therapeutic alliance and openness to reflect on painful memories Reflect on painful memories with optimal arousal Neurobiological Correlate Release of pre synaptic 5 HT1A/1B receptors Increased activity at 5 HT2A receptors Release of dopamine and noradrenaline Increased alpha 2 adrenoreceptor activity Release noradrenaline and cortisol Multiple factors including oxytocin Decreased cerebral blood flow in amygdala & hippocampus Sessa (2017). Neuroscience Letters MDMA Protocol Dose: mg Onset: ~30 60 min Peak effects: ~1 2 hours Half dose: ~1.5 2 hours Annie and Michael Mithoefer Follow and facilitate rather than direct the experience Help explore and validate new perspectives Alternate between talking and periods of inner focus As effects subside, encourage patient to reflect on and accept the validity of the experience Interaction between the effects of the MDMA, the therapeutic setting and the mindsets of the patients and the therapists 14
15 Psychotherapeutic Elements Establishing a Safe and Supportive Therapeutic Setting and a Mindset Conducive to Healing Anxiety Management Training/Stress Inoculation Training Exposure Therapy and Optimal Arousal Cognitive Restructuring Transference and Countertransference Working with the Multiplicity of the Psyche Somatic Manifestations of Trauma Mithoefer. MAPS Bulletin Phase 2 Trial Randomized Double blind Dose response Trial Mithoefer et al. (2018). Lancet Psychiatry Military Veteran, Firefighters, Police Officers CAPS IV > 50 Failed previous pharmacotherapy or psychotherapy Groups: 30 mg (n =7); 75 mg (n = 7); 125 mg (n = 12) Outpatient psychiatric clinic Two blinded session, 3 5 weeks apart with two trained therapists Three prep sessions & post dose daily phone contact for a week and three weekly integration sessions 30 & 75 mg groups crossed over to have 3 open label sessions with flexible dosing ( mg) 15
16 Phase 2 Trial Randomized Double blind Dose response Trial Mithoefer et al. (2018). Lancet Psychiatry Results: CAPS IV change at 1 month follow up (p=0.001): 30 mg: 11.4 [12.7] vs. 75 mg: 58.3 [9.8]; d = mg: 44 3 [28.7] d = mg crossover showed similar improvement CAPS IV change at 12 month follow up (p=.0001): Baseline: 87.1 [16.1] Combined at 12 Month: 38.8 [28.1] 67% no longer met CAPS IV Diagnostic Criteria for PTSD vs 21% in placebo arm Phase 2 Trial Double blind Trial Mithoefer et al. (2018). Lancet Psychiatry 16
17 A Randomized, Double Blind, Placebo Controlled, Multi Site Phase 3 Study of the Efficacy and Safety of Manualized MDMA Assisted Psychotherapy for the Treatment of Severe PTSD Los Angeles, CA private San Francisco, CA academic San Francisco, CA private Boulder, CO private Fort Collins, CO private Farmington, CT academic New Orleans, LA private New York, NY academic New York, NY private Charleston, SC private Madison, WI academic Boston, MA private practice Montreal, Canada private Vancouver, Canada academic Israel private Considerations Safety/abuse Distinguishing from recreational use Blinding/expectancy/naiveté Limited well controlled RCTs Replication Highly selected samples Lack of diverse samples Subjective vs pharmacological properties Funding Implementation & scale Randy.Brown@fammed.wisc.edu 17
MDMA-Assisted Psychotherapy for Treatment of Chronic PTSD: Findings from MAPS-Sponsored Phase 2 Clinical Research Trials
MDMA-Assisted Psychotherapy for Treatment of Chronic PTSD: Findings from MAPS-Sponsored Phase 2 Clinical Research Trials Allison Feduccia, Ph.D. Clinical Trial Leader MAPS Public Benefit Corporation www.maps.org
More informationTHE CUTTING EDGE IN ANXIETY AND DEPRESSION TREATMENT. scott shannon, md university of colorado
THE CUTTING EDGE IN ANXIETY AND DEPRESSION TREATMENT scott shannon, md university of colorado DISCLOSURES I have published two textbooks on integrative mental health. I have published two books on parenting
More informationFar Out Therapies: Psychedelics in Palliative Care. By Dr. Hayden Rubensohn
Far Out Therapies: Psychedelics in Palliative Care By Dr. Hayden Rubensohn Disclosures Dr. Rubensohn is a paid research therapist for the Multidisciplinary Association for Psychedelic Studies (MAPS); affiliated
More informationForward for the Future of Psychiatry
Dr. Ben Sessa MD Child and Adolescent Psychiatrist MDMA Researcher at Bristol and Imperial College London Universities, UK Psychedelics, MDMA, Trauma and Addictions: Bold Steps 5th Meeting of the World
More informationRoyal College of Psychiatrists Annual Meeting. Manchester, UK. September 11 th 2013.
Dr Ben Sessa MBBS BSc MRCPsych Substance Misuse Services, Addaction, North Somerset, UK Honorary Senior Research Fellow, Cardiff University Medical School Royal College of Psychiatrists Annual Meeting.
More informationPsilocybin-assisted therapy for depression. Peak experience, Amygdala changes
Psilocybin-assisted therapy for depression Peak experience, Amygdala changes Psilocybin-assisted therapy n = 20 Treatment resistant major depression Two doses of psilocybin (10mg & 25mg) separated by 1
More informationESALEN INSTITUTE CONTINUING EDUCATION PSYCHOLOGY, MFT/LCSW, LPC, LEP, RN
ESALEN INSTITUTE CONTINUING EDUCATION PSYCHOLOGY, MFT/LCSW, LPC, LEP, RN Leader Name/s: David Presti & Kristi Panik Workshop Title: Psychedelic Medicines and the Mind Workshop Description: Psychedelics
More informationTreating PTSD with MDMA-Assisted Psychotherapy
Treating PTSD with MDMA-Assisted Psychotherapy One out of three people suffering from posttraumatic stress disorder (PTSD) do not respond adequately to treatment. Can MDMA-assisted psychotherapy help?
More informationThe Healing Potential of MDMA
The Healing Potential of MDMA Amy Emerson Director of Clinical Research Multidisciplinary Association for Psychedelic Studies TRI March, 2014 PTSD Traumatic event Event passes, fearful memories remain
More informationThe Benefits of Psychedelic Drug Application for Clinical Treatment of Mental Illness. Timothy Shumate. The University of Kansas School of Nursing
The Benefits of Psychedelic Drug Application for Clinical Treatment of Mental Illness Timothy Shumate The University of Kansas School of Nursing About the author: Tim Shumate is from Wichita, Kansas. He
More informationRead the article, then answer the questions that follow. How MDMA Treats PTSD: Everything You Need to Know
Read the article, then answer the questions that follow. How MDMA Treats PTSD: Everything You Need to Know The party drug is entering the final stages of trials and could be approved for prescription use
More informationHallucinogens as Treatment? Preliminary Data with Ketamine. Elias Dakwar, MD Columbia University College of Physicians and Surgeons 19 October, 2017
Hallucinogens as Treatment? Preliminary Data with Ketamine Elias Dakwar, MD Columbia University College of Physicians and Surgeons 19 October, 2017 Disclosures Elias Dakwar has received funding from NIDA
More informationPharmacological Treatments for Tobacco Users with Behavioral Health Conditions
Pharmacological Treatments for Tobacco Users with Behavioral Health Conditions Jill M Williams, MD Professor Psychiatry Director, Division Addiction Psychiatry Robert Wood Johnson Medical School Disclosures
More informationThis is Your Brain on LSD
This is Your Brain on LSD Kayla Ortiz Rafael Yitzhakian What is LSD? What is LSD? LSD (acid) Lysergic acid diethylamide Hallucinogenic drug Serotonergic psychedelic Banned in the U.S. in the 60 s Classified
More informationEarly History: Ceremonial. The ghost in the machine? examining change phenomena in psychedelic assisted psychotherapy
Early History: Ceremonial The ghost in the machine? examining change phenomena in psychedelic assisted psychotherapy Andrew Penn, RN, MS, NP, APRN-BC Psychiatric Nurse Practitioner Kaiser Permanente Redwood
More informationU.S. 1 February 22, 2013
U.S. 1 February 22, 2013 A Placebo-controlled, Randomized, Blinded, Dose Finding Phase 2 Pilot Safety Study of MDMA-assisted Therapy for Social Anxiety in Autistic Adults Study Code: MAA-1 Sponsor: Multidisciplinary
More informationJOHNS HOPKINS STUDY PROBES SACRED MUSHROOM CHEMICAL
Media Contact: Roland Griffiths, 410 550-0034 JOHNS HOPKINS STUDY PROBES SACRED MUSHROOM CHEMICAL Scientists seek dosage sweet spot, find positive effects lasting over a year Former U.S. Drug Czar raises
More informationCompassionate care and the hope you ve been seeking.
Los Angeles San Diego Compassionate care and the hope you ve been seeking. Our goal is to identify the causes of your suffering, help you find relief through compassionate and effective care, and support
More informationMAPS Study MP-10 1 Study Synopsis UK April 18, 2011
MAPS Study MP-10 1 Study Synopsis A Randomized, Triple-Blind, Phase 2 Pilot Study with an Open-Label Lead-in Comparing 3 Different Doses of MDMA in Conjunction with Manualized Psychotherapy in 20 Subjects
More informationMain Questions. Why study addiction? Substance Use Disorders, Part 1 Alecia Schweinsburg, MA Abnromal Psychology, Fall Substance Use Disorders
Substance Use Disorders Main Questions Why study addiction? What is addiction? Why do people become addicted? What do alcohol and drugs do? How do we treat substance use disorders? Why study addiction?
More informationDisability Risk Management in Today s Workforce: Chronic Pain and Opioid Addiction
Disability Risk Management in Today s Workforce: Chronic Pain and Opioid Addiction Michael V. Genovese, M.D., J.D. Chief Medical Advisor, Acadia Healthcare Recovery Division The vast majority of painful
More informationBack to the Future: Psilocybin Trials in Treatment Resistant Depression in the UK.
Back to the Future: Psilocybin Trials in Treatment Resistant Depression in the UK. James Rucker MBBS BSc MRCPsych PhD Consultant Psychiatrist. South London & Maudsley NHS Trust Senior Clinical Lecturer
More informationDescription of intervention
Helping to Overcome PTSD through Empowerment (HOPE) Johnson, D., Zlotnick, C. and Perez, S. (2011) Johnson, D. M., Johnson, N. L., Perez, S. K., Palmieri, P. A., & Zlotnick, C. (2016) Description of Helping
More informationI DON T KNOW WHY THEY CALL THIS ECSTASY
I DON T KNOW WHY THEY CALL THIS ECSTASY WHAT S GOING ON IN MDMA-ASSISTED PSYCHOTHERAPY FOR PTSD? Royal College of Psychiatrists Faculty of Medical Psychotherapy Annual Conference Cardiff, April 2018 Michael
More informationResearch News. Treating PTSD with MDMA-Assisted Psychotherapy. mdmaptsd.org
MAPS Bulletin Special Edition Research News Treating PTSD with MDMA-Assisted Psychotherapy mdmaptsd.org MDMA capsules from MAPS completed Phase 2 trial of MDMA-assisted psychotherapy for PTSD in Boulder,
More informationMDMA-assisted Psychotherapy for PTSD: An Update of Completed and Ongoing Research
MDMA-assisted Psychotherapy for PTSD: An Update of Completed and Ongoing Research Michael Mithoefer, MD, FAPA Private practice psychiatry & clinical research Clinical Assistant Professor of Psychiatry
More informationOUTPATIENT TREATMENT WESTPORT, CONNECTICUT
OUTPATIENT TREATMENT WESTPORT, CONNECTICUT ABOUT CLEARPOINT At Clearpoint, we focus on healing the whole person: mind, body, and spirit. Our comprehensive care methods set clients up for long-term success
More informationCaron Renaissance. Caron Renaissance
Located in Boca Raton, Florida, offers a unique longer-term continuum of care offering unparalleled behavioral healthcare and clinical services for young adults and adults. Keys to Success Innovator in
More informationPain and Addiction. Edward Jouney, DO Department of Psychiatry
Pain and Addiction Edward Jouney, DO Department of Psychiatry Case 43 year-old female with a history chronic lower back pain presents to your clinic ongoing care. She has experienced pain difficulties
More information9/16/2016. I would feel comfortable dispensing/prescribing varenicline to a patient with a mental health disorder. Learning Objectives
The Smoking Gun: for Smoking Cessation in Patients with Mental Health Disorders BRENDON HOGAN, PHARMD PGY2 PSYCHIATRIC PHARMACY RESIDENT CTVHCS, TEMPLE, TX 09/23/2016 I would feel comfortable dispensing/prescribing
More informationAnnual Report 3,4-methylenedioxymethamphetamine (MDMA) IND Serial Number 0069 Sequential Number 09
Annual Report 3,4-methylenedioxymethamphetamine (MDMA) IND 063384 1571 Serial Number 0069 Sequential Number 09 Reporting Period: 02 October 2015 to 01 October 2016 Date of Report: 27 December 2016 SPONSOR
More informationRelationship Between Stress and Substance Use Disorders: Neurobiologic Interface
Relationship Between Stress and Substance Use Disorders: Neurobiologic Interface Kathleen Brady, M.D., Ph.D. Professor of Psychiatry Associate Dean of Clinical and Translational Research Medical University
More informationTobacco Dependence Treatment From Neurobiology through Public Policy
Tobacco Dependence Treatment From Neurobiology through Public Policy Mary Ellen Wewers, PhD, MPH, RN Professor Emerita The Ohio State University College of Public Health Disclosures Funding from the National
More informationCurriculum Vitae, Lara Goenjian Shirikjian, D.O. Lara Goenjian Shirikjian, D.O. Collaborative Neuroscience Network, LLC
CONTACT INFORMATION: Site Selection and Information: Bobbie Theodore, Alliance Director Tel. (916) 939-6696 Fax (208) 575-3169 Email: clinicaltrials@alliancesites.com AFFILIATIONS: Collaborative Neuroscience
More informationInterventions of Substance Use Disorders. Danica Love Brown, MSW, CACIII, PhD
Interventions of Substance Use Disorders Danica Love Brown, MSW, CACIII, PhD What is Treatment? treatment is defined as the treatment, diagnosis, testing, assessment, or counseling in a professional relationship
More informationNICOTINE PHARMACOLOGY and PRINCIPLES of ADDICTION. 3 rd of 3 Prep for Session 1
NICOTINE PHARMACOLOGY and PRINCIPLES of ADDICTION 3 rd of 3 Prep for Session 1 CHEMISTRY of NICOTINE Pyridine ring N H N CH 3 Pyrrolidine ring Nicotiana tabacum Natural liquid alkaloid Colorless, volatile
More informationThe Impact of Floods on the Mental Health of Children, Adolescents and Their Families. Healthy Minds/Healthy Children Outreach Services 2013
The Impact of Floods on the Mental Health of Children, Adolescents and Their Families Healthy Minds/Healthy Children Outreach Services 2013 1 Disclaimer The information posted in this presentation is made
More informationMENTAL HEALTH AND MENTAL ILLNESS: OUR JOURNEY ACROSS THE CONTINUUM LLI PROGRAM OCTOBER 5, 2018 VIRGINIA F. RIGGS MS, MSN, RN
MENTAL HEALTH AND MENTAL ILLNESS: OUR JOURNEY ACROSS THE CONTINUUM LLI PROGRAM OCTOBER 5, 2018 VIRGINIA F. RIGGS MS, MSN, RN OBJECTIVES: Focus on a continuum from mental health to mental illness Examine
More informationsubstance use and mental disorders: one, the other, or both?
substance use and mental disorders: one, the other, or both? Stephen Strobbe, PhD, RN, PMHCNS-BC, CARN-AP Dawn Farm Education Series St. Joe s Education Center, Ypsilanti, MI Tuesday, January 27, 2015
More informationAdolescents And Addiction
Adolescents And Addiction 1) According to the Substance Abuse and Mental Health Services Administration (SAHMSA), over million people over the age of 12 years needed treatment for substance use in 2012.
More informationCourse Catalog. Early Intervention, Treatment, and Management of Substance Use Disorders
Course Catalog To take a course, visit our website at https://www.mindfulceus.com - You can link directly to a course by visiting https://www.mindfulceus.com/course/id where ID is the ID number listed
More informationMinneapolis VA s Intensive Outpatient Program (IOP): Screening, Treating, and Tracking Veterans
Minneapolis VA s Intensive Outpatient Program (IOP): Screening, Treating, and Tracking Veterans Stephanie Bertucci, LICSW, IOP Coordinator Marcus Moore, Certified Peer Specialist Daniel Silversmith, PsyD,
More informationLong-term follow-up of psilocybin-facilitated smoking cessation
THE AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE 217, VOL. 43, NO. 1, 55 6 http://dx.doi.org/1.319/95299.216.117135 ORIGINAL ARTICLE Long-term follow-up of psilocybin-facilitated smoking cessation Matthew
More informationCOGNITIVE BEHAVIOR THERAPY (CBT) & DIALECTICAL BEHAVIOR THERAPY (DBT)
COGNITIVE BEHAVIOR THERAPY (CBT) & DIALECTICAL BEHAVIOR THERAPY (DBT) Kim Bullock, MD Clinical Associate Professor, Director of Neurobehavioral Clinic Director of Virtual Reality Therapy Lab Department
More informationLos Angeles, California
Los Angeles, California Compassionate care and the hope you ve been seeking. Our goal is to identify the causes of your suffering, help you find relief through compassionate and effective care, and support
More informationAddressing the Opioid Epidemic by Maximizing Behavioral Treatment in Chronic Non-Cancer Pain
Addressing the Opioid Epidemic by Maximizing Behavioral Treatment in Chronic Non-Cancer Pain Aleksandra Zgierska, MD PhD University of Wisconsin-Madison Robert Edwards, PhD Brigham and Women s Hospital
More informationSUBSTANCE USE DISORDER IN ADOLESCENT POPULATION
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences SUBSTANCE USE DISORDER IN ADOLESCENT POPULATION ANNABELLE SIMPSON, MD UNIVERSITY OF WASHINGTON GENERAL DISCLOSURES
More informationImpact on our Mental Health. Biological Changes Psychological Changes Social Changes Professional Services Coping Skills
Impact on our Mental Health Biological Changes Psychological Changes Social Changes Professional Services Coping Skills Biological Changes After a brain injury, biological impacts may affect mental health
More informationPsychological and Psychosocial Treatments in the Treatment of Borderline Personality Disorder
Psychological and Psychosocial Treatments in the Treatment of Borderline Personality Disorder The Nice Guidance for the Psychological and Psychosocial treatment of Borderline Personality Disorder (BPD)
More informationConcurrent Disorders
Concurrent Disorders Dr. Christy Sutherland MD CCFP dipabam Medical Director, PHS Community Services Methadone/Buprenorphine 101 Workshop April 1, 2017 Overview Introduction Epidemiology Treatment Principles
More informationErowid Wisdom Cycle Survey #1 April 15, 2013
Erowid Wisdom Cycle Survey #1 April 15, 2013 Purpose This survey is part of a project to gather wisdom and life lessons related to the use of psychedelics, empathogens, and cannabis. In part, we are exploring
More informationAdolescents And Addiction
Adolescents And Addiction 1) According to the Substance Abuse and Mental Health Services Administration (SAHMSA), over million people over the age of 12 years needed treatment for substance use in 2012.
More informationTRAUMA INFORMED CARE: THE IMPORTANCE OF THE WORKING ALLIANCE
TRAUMA INFORMED CARE: THE IMPORTANCE OF THE WORKING ALLIANCE Justin Watts PhD. NCC, CRC Assistant Professor, Rehabilitation Health Services The University of North Texas Objectives Upon completion of this
More informationAnnual Report 3,4-methylenedioxymethamphetamine (MDMA) IND Form 1571 Serial Number: 0060 Sequential Number 08
Annual Report 3,4-methylenedioxymethamphetamine (MDMA) IND 063384 Form 1571 Serial Number: 0060 Sequential Number 08 Reporting Period: October 2, 2014 to October 1, 2015 Version Date: January 4, 2016 SPONSOR
More informationStates of Consciousness Day 2
States of Consciousness Day 2 Hypnosis* l Hypnosis: involves a state of awareness characterized by deep relaxa6on, heightened sugges6bility, and focused a:en6on. l Hypno6st suggests changes in sensa6ons,
More informationCBT for Hypochondriasis
CBT for Hypochondriasis Ahmad Alsaleh, MD, FRCPC Assistant Professor of Psychiatry College of Medicine, KSAU-HS, Jeddah Agenda Types of Somatoform Disorders Characteristics of Hypochondriasis Basic concepts
More informationTopic: GHB / Ecstasy Target Group: Grades Prepared By: Neil Wagstrom Agency: Glenwood Springs P. D.
Corbin & Associates, Inc. Lesson Plan of the Month December 2000 Topic: GHB / Ecstasy Target Group: Grades 10-12 Prepared By: Neil Wagstrom Agency: Glenwood Springs P. D. Address: 823 Blake Ave. Phone:
More informationKatarina R. Mansir, Psy.D. Licensed Psychologist PSY25417 (858) Name: Date: Presenting Concerns
Name: Date: Presenting Concerns Briefly describe what brings you to therapy. Approximately how long has this concern been bothering you? Day Week Month Several months Year Several years Most of my life
More informationPsychedelics. Neal Deot & Amir Hakimi
Psychedelics Neal Deot & Amir Hakimi Psychedelics Psychedelic comes from the Greek words psyche (soul) and delein (to manifest) = soul-manifesting Often compared to non-ordinary forms of consciousness:
More informationUnderstanding Addiction: Why Can t Those Affected Just Say No?
Understanding Addiction: Why Can t Those Affected Just Say No? 1 The Stigma of Addiction There continues to be a stigma surrounding addiction even among health care workers. Consider the negative opinions
More information2017 ADDICTION PROGRAM PACKAGE
2017 ADDICTION PROGRAM PACKAGE WHO WE ARE The Habitude Program offers an authentic Bio-Psycho-Social approach with holistic principles and modalities. Since 2005, our in-patient program has helped individuals
More informationDr. Meldon Kahan. Women s College Hospital. with PIA LAW
with PIA LAW and Toronto ABI Network Dr. Meldon Kahan Women s College Hospital Dr. Meldon Kahan is an Associate Professor in the Department of Family Medicine at University of Toronto, and Medical Director
More informationStressed out! The science and practice of stress management. Bonnie A. McGregor, Ph.D.
Stressed out! The science and practice of stress management Bonnie A. McGregor, Ph.D. % endorsing item (n = 134) Cancer survivors beliefs about cancer causes 60 50 40 30 20 10 0 Genetics Stress God's will
More informationPersonality Disorders. Mark Kimsey, M.D. March 8, 2014
Personality Disorders Mark Kimsey, M.D. March 8, 2014 Objectives Understanding personality disorders using criteria from DSM-5. Learn approaches for separating personality disorders from other major illnesses.
More informationPratik U. Patel, Psy.D.
Pratik U. Patel, Psy.D. 8920 Wilshire Blvd. Suite 334 Beverly Hills, CA 90211 (323) 489-5880 EDUCATION The Chicago School of Professional Psychology, Los Angeles CA, September, 2012 October, 2015 Doctor
More informationWhat Are Hallucinogens? (National Institute on Drug Abuse; National Institutes of Health; U.S. Department of Health and Human Services)
What Are Hallucinogens? (National Institute on Drug Abuse; National Institutes of Health; U.S. Department of Health and Human Services) Hallucinogens are a diverse group of drugs that alter perception
More informationTrigger. Myths About the Use of Medication in Recovery BUPRENORPHINE TREATMENT: A TRAINING FOR MULTIDISCIPLINARY ADDICTION PROFESSIONALS
BUPRENORPHINE TREATMENT: A TRAINING FOR MULTIDISCIPLINARY ADDICTION PROFESSIONALS Module VI Counseling Buprenorphine Patients Myths About the Use of Medication in Recovery! Patients are still addicted!
More informationComorbidity With Substance Abuse P a g e 1
Comorbidity With Substance Abuse P a g e 1 Comorbidity With Substance Abuse Introduction This interesting session provided an overview of recent findings in the diagnosis and treatment of several psychiatric
More informationCognitive Behavioral Therapy (CBT) for Substance Use Disorder
Cognitive Behavioral Therapy (CBT) for Substance Use Disorder John F. Kelly, Ph.D. 1 Disclosures Neither I nor my spouse/partner has a relevant financial relationship with a commercial interest to disclose.
More informationPROFESSIONAL BACKGROUND: I am a psychiatrist in private practice in. Watertown, Massachusetts (see attached resume). I have a longstanding
TESTIMONY FOR MDMA HEARING... Submitted by: Richard Ingrasci, M.D., M.P.H. 173 Mr. Auburn St., Watertown, MA 02172 (617) 923-4601 PROFESSIONAL BACKGROUND: I am a psychiatrist in private practice in Watertown,
More informationSupporting Information
Supporting Information Carhart-Harris et al. 10.1073/pnas.1119598109 Fig. S1. Slices for arterial spin labeling (ASL) result. Lightbox display of slices showing regions where there were significant decreases
More informationPsychosocial intervention to optimal treatment to patients with schizophrenia: neurocognitive perspectives
Psychosocial intervention to optimal treatment to patients with schizophrenia: neurocognitive perspectives TANG Tze-Chun Department of psychiatry KMUH Pharmacotherapy alone or combination with psychotherapy?
More informationUNC-CH School of Social Work Clinical Lecture Series
UNC-CH School of Social Work Clinical Lecture Series Michael C. Lambert, PhD Professor and Licensed Psychologist with HSP Cert. March 7, 2016 It is not a diagnostic category recognized by the DSM or ICD
More informationPerformance of Initiating Q South London and Maudsley NHS Foundation Trust:
Research Ethics Committee Reference Number Integrated Research Application System Number Submission Type Name of Trial Date of Receipt of Valid Research Application Date of NHS First Patient Recruited?
More informationBRIGHAM AND WOMEN S FAULKNER HOSPITAL ADULT INPATIENT PSYCHIATRY ADVANCED PRACTICUM TRAINING PROGRAM
BRIGHAM AND WOMEN S FAULKNER HOSPITAL ADULT INPATIENT PSYCHIATRY ADVANCED PRACTICUM TRAINING PROGRAM 2019-2020 Christopher AhnAllen, Ph.D. Director of Inpatient Psychology and Psychology Education 1153
More informationTreating Complex Trauma, Michael Lambert, Ph.D. 3/7/2016
UNC-CH School of Social Work Clinical Lecture Series Michael C. Lambert, PhD Professor and Licensed Psychologist with HSP Cert. March 7, 2016 It is not a diagnostic category recognized by the DSM or ICD
More informationCHAPTER 16. Trauma-Related Disorders in Children. Trauma, Stressorrelated, and. Dissociative Disorders
in Children Clinical Picture CHAPTER 16 Posttraumatic stress disorder in preschool children Reactive attachment disorder Trauma, Stressorrelated, and Disinhibited social engagement disorder 1 Trauma-related
More informationΝευροφυσιολογία και Αισθήσεις
Biomedical Imaging & Applied Optics University of Cyprus Νευροφυσιολογία και Αισθήσεις Διάλεξη 19 Ψυχασθένειες (Mental Illness) Introduction Neurology Branch of medicine concerned with the diagnosis and
More informationKids Help Phone: How We Engage Youth
Kids Help Phone: How We Engage Youth May 25, 2017 Presented by: Alisa Simon VP, Counselling Services and Programs Alisa.simon@kidshelpphone.ca The counsellor was really nice, and I m glad I had someone
More informationINDEX. P. 2 Provisional List of Potentially Harmful Therapies (Adapted from Lilienfeld, 2007)
Comprehensive List of Currently-Identified Potentially Harmful (PHTs) and Empirically Supported Psychological Treatments (ESTs) for Adults, Adolescents, and Children INDEX P. 2 Provisional List of Potentially
More informationKey Concepts. Machinery of the Mind. The Growing Cycle. Six Brain Mind Functions. Machinery of the Mind 6/1/2012
Machinery of the Mind How High-risk Choices Redesign the Brain Key Concepts Brain and Mind are reciprocal Brain/Mind Functions intertwine We are hardwired and we have software Your brain changes all the
More informationSubstance Use Disorders
Substance Use Disorders Substance Use Disorder This is a 15 minute webinar session for CNC physicians and staff CNC holds webinars monthly to address topics related to risk adjustment documentation and
More informationChapter 10 Suicide Assessment
Chapter 10 Suicide Assessment Dr. Rick Grieve PSY 442 Western Kentucky University Not this: Suicide is man s way of telling God, You can t fire me, I quit. Bill Maher 1 Suicide Assessment Personal Reactions
More informationDay Programs. Information for patients, carers, family and support persons
Day Programs Information for patients, carers, family and support persons Sometimes the smallest step in the right direction ends up being the biggest step of your life. Tip toe if you must, but take the
More informationIf gambling treatment was evidence based, what would it look like?
If gambling treatment was evidence based, what would it look like? Professor Mark Griffiths International Gaming Research Unit Nottingham Trent University E-mail : mark.griffiths@ntu.ac.uk Website :http://ess.ntu.ac.uk/griffiths
More informationResearch News. Treating PTSD with MDMA-Assisted Psychotherapy. mdmaptsd.org
Research News Treating PTSD with MDMA-Assisted Psychotherapy mdmaptsd.org 20th Subject Treated in Ongoing Veterans Study; Study Fully Funded Ongoing study Location: Charleston, South Carolina Principal
More informationListen & Hear 4Lo
Mark Lim M.D FASAM Medical Director NorthLakes Community Clinic Recovery Program Board Certified in Family Medicine Board Certified in Addiction Medicine mlim@northlakesclinic.org 7156852200 Listen & Hear
More informationCBT FOR PRIMARY CARE PART 1: BACKGROUND AND THEORY DISCLOSURES
CBT FOR PRIMARY CARE PART 1: BACKGROUND AND THEORY Neil Skolnik, M.D. Professor of Family and Community Medicine Temple University School of Medicine Associate Director Family Medicine Residency Program
More informationBORDERLINE PERSONALITY DISORDER: A LITTLE COMPASSION CAN GO A LONG WAY
BORDERLINE PERSONALITY DISORDER: A LITTLE COMPASSION CAN GO A LONG WAY Jean Clore, PhD, LCP Associate Program Director & Assistant Professor Department of Psychiatry & Behavioral Medicine University of
More informationMindful Stress Reduction
Amy Carlson, LCSW TURNING POINT COUNSELING SERVICES Mindful Stress Reduction TODAY S PRESENTATION How to recognize symptoms of stress in the body and stress in the brain. The long-term effects of stress
More informationRecent Advances in the Treatment of Post Traumatic Stress Disorder. Jon Bisson School of Medicine Cardiff University
Recent Advances in the Treatment of Post Traumatic Stress Disorder Jon Bisson School of Medicine Cardiff University Agenda What are we treating Psychological approaches Pharmacological approaches Treatment
More informationOutline 3/5/2013. Practice Question. Practice question. PSYC 120 General Psychology. Spring 2013 Lecture 11: States of consciousness
Outline 3/5/2013 PSYC 120 General Psychology Spring 2013 Lecture 11: States of consciousness The Nature of Consciousness Sleep and Dreams Psychoactive Drugs Hypnosis Meditation Dr. Bart Moore bamoore@napavalley.edu
More informationINDEX. B Behavioral activation, 121 competence, 38 flexibility, 29, 110 health, 2, 7, 8, 16, , 127, 144 management, 128
INDEX A Academic performance, 58, 91, 94, 99 Academic scores, 58 Academic skills, 79 Acceptance, 4, 57, 61, 64, 65, 78, 81, 88, 91, 107, 110 112, 114, 120 123, 128, 134, 139, 148, 151, 157 commitment therapy
More information5/9/2016 COMPLEX TRAUMA OVERVIEW COMPLEX TRAUMA: DEFINED
COMPLEX TRAUMA Elizabeth C. Risch, Ph.D. Melissa Bernstein, Ph.D. OVERVIEW What is Complex Trauma? Impact on therapeutic relationship Adapting TF-CBT to best fit this population Phase Based Approach COMPLEX
More informationPreventing Compassion Fatigue and Burnout. Jenn Hannigan MD CCFP(PM) Mar.14, 2017
Preventing Compassion Fatigue and Burnout Jenn Hannigan MD CCFP(PM) Mar.14, 2017 Objectives Recognize signs and symptoms of compassion fatigue and burnout Understand mitigating factors and strategies proven
More informationDialectical Behaviour Therapy in an Outpatient Drug and Alcohol Setting
Dialectical Behaviour Therapy in an Outpatient Drug and Alcohol Setting Distinguishing features of DBT Implementing DBT within Drug Health Services RPAH Case Study Background to DBT Developed in early
More informationSECTION 1. Children and Adolescents with Depressive Disorder: Summary of Findings. from the Literature and Clinical Consultation in Ontario
SECTION 1 Children and Adolescents with Depressive Disorder: Summary of Findings from the Literature and Clinical Consultation in Ontario Children's Mental Health Ontario Children and Adolescents with
More informationTherapeutic mechanisms of classic hallucinogens in the treatment of addictions: from indirect evidence to testable hypotheses
Review Received: 1 January 2012 Revised: 30 April 2012 Accepted: 30 April 2012 Published online in Wiley Online Library (www.drugtestinganalysis.com) DOI 10.1002/dta.1376 Therapeutic mechanisms of classic
More informationThe Variations of 5-MeO-DMT Mystical Experiences and Considerations for the Future
The Variations of 5-MeO-DMT Mystical Experiences and Considerations for the Future Dr. Joseph Barsuglia World Bufo Alvarius Congress, Mexico City July 2018 Research Psychologist: Personal Background Crossroads
More informationOrganization: NAMI Minnesota Request ID: Program Title: Reducing Smoking Among People with Mental Illnesses
Organization: NAMI Minnesota Request ID: 16872475 Program Title: Reducing Smoking Among People with Mental Illnesses 1. Overall Goal & Objectives The overall goal of this project is to reduce the rate
More information